Details

Autor(en) / Beteiligte

• Yoshida, Yoichiro
• Naito, Masayasu
• Yamada, Teppei
• Aisu, Naoya
• Daibo, Kojima
• Mera, Toshiyuki
• Tanaka, Toshihiro
• Naito, Keiko
• Yasumoto, Kosei
• Kamigaki, Takashi
• Goto, Shigenori
• Yamashita, Yuichi
• Hasegawa, Suguru

Titel

Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer

Ist Teil von

• Anticancer research, 2016-07, Vol.36 (7), p.3741

Ort / Verlag

Greece

Erscheinungsjahr

2016

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large numbers of αβ and γδ T cells. We evaluated the safety and efficacy of the combination of adoptive immunotherapy using αβ T cells with chemotherapy for stage IV colorectal cancer (CRC). Fifteen patients with advanced or recurrent CRC received XELOX + bevacizumab + ex vivo expanded αβ T lymphocytes as a first-line chemoimmunotherapy. Median age of the 15 patients (4 men, 11 women) was 65 years (range=49-80). Median progression-free survival was 21.3 months. Response rate was 80% (complete response (CR)=26.7%, partial response (PR)=53.3%, stable disease (SD)=20% and progressive disease (PD)=0%). Most adverse events were mild to moderate regarding their intensity and immunotherapy-associated toxicity was minimal. Combination of adoptive αβ T cell immunotherapy with chemotherapy for stage IV CRC is feasible and safe.